RecruitingPhase 2NCT06453694
Efgartigimod for the Treatment of Acute Optic Neuritis
Studying Isolated optic neuritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Anastasia Vishnevetsky, MD, MPH
- Principal Investigator
- Anastasia Vishnevetsky, MD, MPHMassachusetts General Hospital
- Intervention
- Efgartigimod Alfa(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2027
Study locations (2)
- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
Collaborators
argenx
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06453694 on ClinicalTrials.gov